Radiation and immunotherapy for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests different doses of radiation therapy combined with the immunotherapy drug sintilimab for people with locally advanced esophageal squamous cell carcinoma. The goal is to find the best radiation dose to improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with locally advanced esophageal squamous cell carcinoma (a type of esophageal cancer).
- You have at least one measurable tumor (a tumor that can be seen on scans).
- You are in good physical condition (able to do daily activities without help), as measured by a score of 0-1.
- Your organs (like liver, kidneys, etc.) are working well enough for the treatment.
- You have not had any prior treatment for this cancer (like radiation, chemo, immunotherapy, or traditional Chinese medicine).
- You do not have any other active cancer in the last 5 years (except for cured skin cancers or very early-stage cancers).
- Your tumor is not invading nearby organs (like the aorta or windpipe) in a way that could cause bleeding or a hole (fistula).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests a short course of radiation combined with an immunotherapy drug called sintilimab before surgery for esophageal squamous cell carcinoma. The goal is to see if this combination can shrink the tumor and improve treatment outcomes.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.